AstraZeneca's Iressa May Pave Way For EGFR Inhibitors In Adjuvant Lung Cancer
Executive Summary
Study done in China may prompt a change the standard of care in the US to include earlier testing for EGFR mutations after surgery, but is unlikely to change treatment protocols until overall survival data are available.
You may also be interested in...
AstraZeneca Upbeat On China Prospects For New Products
China continues to be the brightest star in AstraZeneca's emerging markets firmament amid some "softness" in other countries, and the UK group sees attractive prospects in the country for some of its innovative branded products.
AstraZeneca’s Iressa, Now Resurrected, Faces Daunting U.S. EGFR Market
AstraZeneca sees an edge on safety for Iressa, which was traditionally perceived as having attractive tolerability relative to other EGFR inhibitors, but firm still has a tough road competing against the omnipresent Tarceva.
AstraZeneca's Iressa Use Narrowed: No New Commercial Patients
Revised labeling for the oncologic restricts use to patients who have already received the drug and benefited from it, as well as certain clinical trial participants. Beginning Sept. 15, Iressa patients will have to refill prescriptions through a single mail order pharmacy.